AbbVie has announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for the combination of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The regulatory decision is supported by results from the Phase 3 AMPLIFY trial, marking a significant development in the first-line treatment landscape for the disease.
With this approval, the VENCLEXTA plus acalabrutinib regimen becomes the first and only all-oral, fixed-duration combination therapy authorized for previously untreated CLL patients. The regimen combines two targeted oral agents from different therapeutic classes and is designed to offer patients a time-limited treatment option, potentially allowing periods off therapy once the course is completed.
CLL, one of the most common forms of leukemia in adults, originates in the bone marrow and affects a subset of white blood cells known as lymphocytes. Although therapeutic advances over the past decade have improved patient outcomes, many individuals still require extended or continuous treatment, leading to long-term management challenges and potential cumulative side effects.
AbbVie executives emphasized the importance of expanding frontline treatment options. Svetlana Kobina, vice president of global medical affairs in oncology at AbbVie, described the approval as a milestone both for the company and for patients living with CLL. She noted that introducing the first all-oral, fixed-duration combination in the first-line setting provides additional flexibility for patients and healthcare providers navigating increasingly complex treatment decisions.
Patient advocacy groups also welcomed the development. Dr. Brian Koffman, co-founder and chief medical officer emeritus of the CLL Society, highlighted the significance of having an all-oral, time-limited frontline option available in the United States. He said that expanding the number of treatment choices can be crucial for patients weighing the benefits and trade-offs of different therapeutic strategies.
The approval reflects continued progress in targeted cancer therapies, particularly in hematologic malignancies. By combining venetoclax, a BCL-2 inhibitor, with acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, the regimen addresses CLL through complementary mechanisms of action. The AMPLIFY trial data demonstrated the combination’s ability to meet key clinical endpoints, paving the way for its use as an initial treatment.
As the CLL treatment landscape evolves, the introduction of a fixed-duration, oral-only combination may reshape expectations for frontline care, offering patients the potential for effective disease control without indefinite therapy.